Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OK-101 in Dry Eye Disease
NCT05759208Phase 2Completed
- Sponsor
- OKYO Pharma Limited
- Start
- Apr 2023
- Primary completion
- Dec 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of urcosimod in dry eye disease (DED), sponsored by OKYO Pharma Limited. Started Apr 2023; status: completed.
02
Drugs
urcosimod
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05759208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759208.